Global Trigeminal Neuralgia Treatment Market Size Projected to Reach $411.57 million by 2034 | 4.9%

The global trigeminal neuralgia (TN) treatment market size was valued at USD 267.59 million in 2025 and is projected to grow from USD 280.7 million in 2026 to USD 411.57 million by 2034 at a CAGR of 4.9% during the forecast period 2026-2034.

Trigeminal neuralgia (TN) is a rare disorder that causes severe chronic pain due to damage to the trigeminal nerve, which transfers sensation from the face to the brain. It is primarily caused by blood vessels pressing towards the root of the trigeminal nerve, which helps the nerve transmit signs of discomfort that are felt as stabbing pains. Symptoms vary from moderate to extreme facial discomfort, which is often caused by teeth grinding, talking, or brushing.

Rising Popularity of Anticonvulsant Medications in the Treatment of Trigeminal Neuralgia

Anticonvulsant medications are formulated specifically for the treatment of epilepsy. As per WHO statistics, epilepsy affects about 50 million people globally. The increasing incidence of TN will increase the adoption of anticonvulsants. As per the American Association of Neurological Surgeons, an estimated 150,000 people are diagnosed with TN every year. Anticonvulsants are gaining popularity as they are effective in treating TN. Carbamazepine drugs, such as Tegretol and Carbatrol, are commonly used anticonvulsants. Other anticonvulsant drugs that may be used include oxcarbazepine (Trieptal), lamotrigine (Lamictal), and phenytoin (Dilantin, Phenytek). However, patients face a substantial burden of illness and multiple side effects by prolonged usage of drugs, such as amnesia, nausea, drowsiness, dizziness, and unstableness.

Extensive Drug Pipeline for Trigeminal Neuralgia Treatment, Comprising Chemicals and Biologics

The drug pipeline in Tennessee is extensive and composed of a mixture of chemicals and biologics. However, in phase III of clinical trials, the number of chemical-based drug molecules is higher than that of biological drugs. Improved innovative drugs are a welcome addition to meet the unmet needs of trigeminal neuralgia patients and will create a lucrative opportunity for the market in the coming years.

• Among the emerging treatment options currently under clinical investigation are local botulinum neurotoxin type A injections and a novel sodium channel blocker (CNV1014802) that selectively blocks the Nav1.7 sodium channel.
• Non-pharmacological treatment options include non-invasive electrical stimulation with either transcranial direct-current stimulation or repetitive transcranial magnetic stimulation, both of which require further evaluation in regard to applicability.

Trigeminal Neuralgia Treatment Market: Highlights

• The global companion diagnostics market size reached USD 8.98 billion in 2025 and is anticipated to grow from USD 10.09 billion in 2026 to USD 25.58 billion by 2034, expanding at a CAGR of 12.33% over the forecast period from 2026 to 2034, due to the expanding geriatric population and the increasing prevalence of TN.
• Under the drugs segment by treatment type, carbamazepine leads the trigeminal neuralgia treatment market and held a value share worth USD 53.44 million in 2019. Anticonvulsants are gaining popularity as they are effective in treating TN. The anticonvulsant carbamazepine is currently the only medicine licensed to treat TN in the U.K., as per the NHS UK.
• Increasing spending on healthcare, rising awareness about medical therapies, and the growing acceptance of customized medication are expected to push the adoption of oxcarbazepine around the globe.
• By region, North America dominates the trigeminal neuralgia treatment market with a share of 39% in 2019.
• Asia-Pacific is estimated to register the fastest growth, with a CAGR of around 6.9% during the forecast study, owing to the high prevalence of TN in the region and the strong distribution network in pharma-emerging nations.
• The existence of a robust pipeline and the acceptance of new medicines are projected to fuel the development of the global trigeminal neuralgia treatment market during the forecast period.
• Key players operating in the trigeminal neuralgia treatment market include GlaxoSmithKline plc, Pfizer Inc., Trigemina, Inc., Novartis Pharmaceuticals Corporation, Sun Pharmaceutical Industries Ltd.., Lupin Pharmaceuticals, Inc., Apotex Inc., Dr. Reddy’s Laboratories Ltd, and Biogen.

Market Segments

1. By Treatment Type
   
   1. Drugs
      1. Carbamazepine
      2. Oxcarbazepine
      3. Others
   2. Surgeries
      1. Microvascular decompression 
      2. Stereotactic Radiosurgery
      3. Percutaneous Procedures
2. By Treatment Provider
   1. Hospitals and Clinics
   2. Ambulatory Surgery Centres
   3. Others